Omega-3 Heart Health Claims Decision: FDA Out Of Step With Industry?
Executive Summary
"The reality is that the FDA remains unwilling to rely upon a meta-analysis of only the highest quality studies in order to guide its final decision," GOED VP Harry Rice. "I think FDA has really lost sight of how the dietary supplement industry has changed," says attorney Charles Jolly.
You may also be interested in...
US Omega-3 Supplement Firm Changes Claims On Amarin Challenge, But Not Label Or Company Name
National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.
Magnesium Qualified Health Claims For Reducing Risk Of Hypertension Authorized In US
CFSAN decides on Center for Magnesium Education and Research LLC's 2016 petition requesting FDA authorize a qualified health claim about relationship between magnesium and reduced risk of high blood pressure, or hypertension.
US FDA Again Stops At Qualified Health Claim For Supplements: Cranberry Reduces UTI Risk
FDA intends to exercise enforcement discretion regarding QHCs about the association between reduced risk of recurrent UTI and use of supplements with at least 500 mg cranberry fruit powder and of cranberry juice beverages containing at least 27% cranberry juice.